Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amy Turner

Physician Assistant Summerville, SC Physician Assistant

NPI 1215261672 CMS profile 11098536

204 Parsons Rd, Summerville, SC 29483

Open in the dashboard

General payments

$13,389

676 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Turner of Summerville, SC is reported in the CMS Open Payments database as having received $13,389 across 676 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,580 121
2024 General $2,038 91
2023 General $2,849 126
2022 General $2,508 139
2021 General $3,414 199

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Turner
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Amy Turner were reported at $2,580. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Amy Turner Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $3,414 $132 $37–$438 $132
2022 $2,508 $155 $48–$522 $149
2023 $2,849 $167 $52–$557 $160
2024 $2,038 $178 $55–$600 $164
2025 $2,580 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Lilly USA, LLC $1,553 79 payments
  2. Novo Nordisk Inc $1,444 87 payments
  3. Abbott Laboratories $1,089 50 payments
  4. AbbVie, Inc. $790 46 payments
  5. Medtronic, Inc. $719 34 payments
  6. Xeris Pharmaceuticals, Inc. $717 40 payments
  7. Sanofi-Aventis U.S. LLC $692 28 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $651 32 payments
  9. Corcept Therapeutics $484 23 payments
  10. Insulet Corporation $443 15 payments
  11. Other $4,807 242 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,326 674 payments
  2. Education $62 2 payments
Products named General payments · program years 2021–2025
  1. Ozempic $1,023 64 payments
  2. FreeStyle Libre $859 40 payments
  3. DUPIXENT $855 24 payments
  4. JARDIANCE $714 36 payments
  5. MINIMED 780G $659 30 payments
  6. Kerendia $651 32 payments
  7. MOUNJARO $562 28 payments
  8. Korlym $484 23 payments
  9. Omnipod $443 15 payments
  10. TRULICITY $442 23 payments
  11. Other $8,959 481 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

2,490

Median for Physician Assistant: 241

Drug cost

$1,465,611

Median for Physician Assistant: $4,110

Branded share of claims

62.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 237 $390,255
Mounjaro Tirzepatide Brand 231 $353,782
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 103 $158,731
Trulicity Dulaglutide Brand 71 $107,423
Jardiance Empagliflozin Brand 66 $88,453
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 44 $38,120
Farxiga Dapagliflozin Propanediol Brand 54 $37,968
Januvia Sitagliptin Phosphate Brand 35 $29,618
Tresiba Flextouch U-200 Insulin Degludec Brand 32 $29,136
Tresiba Flextouch U-100 Insulin Degludec Brand 37 $25,436

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$43,132

Medicare's payments for the services billed

Medicare patients

206

Average age 71

Services billed

778

135 women, 71 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 68%
Arthritis 52%
Chronic kidney disease 30%
Ischemic heart disease 26%
Depression 26%
Osteoporosis 17%
Heart failure 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Ozempic
  • Novo Nordisk Inc $217
$217 237 —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $183
$183 — —
MOUNJARO
  • Lilly USA, LLC $135
$135 231 —
JARDIANCE
  • Lilly USA, LLC $81
  • Boehringer Ingelheim Pharmaceuticals, Inc. $28
$110 66 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

676 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record